GoodRx: Stabilizing Revenue Amid Healthy Profit Gains

A 'Buy' rating is reiterated for GoodRx (GDRX), citing a compelling valuation and signs of business stabilization under new leadership. The recurring revenue base, expanding pharma partnerships, and robust EBITDA margins support a potential rebound, with double-digit growth in the direct pharma channel offsetting headwinds like Rite Aid's bankruptcy. At 6x FY25 adjusted EBITDA, the analyst believes GoodRx's risks are priced in, positioning it as an attractive small-cap value play and possible acquisition target.

Analysis

GoodRx (GDRX) has received a reiterated 'Buy' rating, underpinned by a compelling valuation and discernible signs of business stabilization under new leadership. The company's investment thesis is supported by a recurring revenue base, expanding partnerships within the pharmaceutical sector, and robust EBITDA margins. Notably, GoodRx's direct pharma channel is demonstrating significant strength with double-digit growth, which is effectively offsetting persistent headwinds such as the Rite Aid bankruptcy and flat overall consumer growth. Trading at an estimated 6 times FY25 adjusted EBITDA, the current valuation is perceived to have already factored in existing operational risks. This financial profile positions GoodRx as an attractive small-cap value proposition and also flags it as a potential acquisition target, aligning with the strongly positive sentiment (0.8) and bullish tone identified.

Key Decisions for Investors

• Investors may consider GoodRx an attractive opportunity, particularly those seeking exposure to small-cap value stocks, given its current valuation and signs of operational stabilization.
• Monitor the sustained double-digit growth in GoodRx's direct pharma channel and its effectiveness in mitigating the impact of Rite Aid's bankruptcy and stagnant consumer growth as key performance indicators.
• The potential for GoodRx to become an acquisition target could serve as an additional catalyst for share price appreciation and should be considered in investment strategies.